348 related articles for article (PubMed ID: 35525394)
1. Emerging roles of extracellular vesicles in polyglutamine diseases: Mutant protein transmission, therapeutic potential, and diagnostics.
Takeuchi T; Nagai Y
Neurochem Int; 2022 Jul; 157():105357. PubMed ID: 35525394
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic and protective roles of extracellular vesicles in neurodegenerative diseases.
Takeuchi T
J Biochem; 2021 Mar; 169(2):181-186. PubMed ID: 33196835
[TBL] [Abstract][Full Text] [Related]
3. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture.
Zhang X; Abels ER; Redzic JS; Margulis J; Finkbeiner S; Breakefield XO
Cell Mol Neurobiol; 2016 Apr; 36(3):459-70. PubMed ID: 26951563
[TBL] [Abstract][Full Text] [Related]
4. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
Nagai Y; Popiel HA
Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
[TBL] [Abstract][Full Text] [Related]
5. Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.
Takeuchi T; Nagai Y
Brain Sci; 2017 Oct; 7(10):. PubMed ID: 29019918
[TBL] [Abstract][Full Text] [Related]
6. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
[TBL] [Abstract][Full Text] [Related]
7. Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability.
Hashimoto M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Masliah E; Waragai M
J Huntingtons Dis; 2018; 7(4):297-307. PubMed ID: 30372687
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
[TBL] [Abstract][Full Text] [Related]
9. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].
Nagai Y; Nukina N
Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499
[TBL] [Abstract][Full Text] [Related]
10. Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.
Takeuchi T; Popiel HA; Futaki S; Wada K; Nagai Y
Curr Med Chem; 2014; 21(23):2575-82. PubMed ID: 24533807
[TBL] [Abstract][Full Text] [Related]
11. Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases.
Xia X; Wang Y; Zheng JC
Transl Neurodegener; 2022 Dec; 11(1):53. PubMed ID: 36510311
[TBL] [Abstract][Full Text] [Related]
12. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicles and Neurodegenerative Diseases.
Hill AF
J Neurosci; 2019 Nov; 39(47):9269-9273. PubMed ID: 31748282
[TBL] [Abstract][Full Text] [Related]
14. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
Nagai Y
Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
[TBL] [Abstract][Full Text] [Related]
15. Astrocyte-derived extracellular vesicles: Neuroreparative properties and role in the pathogenesis of neurodegenerative disorders.
Upadhya R; Zingg W; Shetty S; Shetty AK
J Control Release; 2020 Jul; 323():225-239. PubMed ID: 32289328
[TBL] [Abstract][Full Text] [Related]
16. Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.
Tower C; Fu L; Gill R; Prichard M; Lesort M; Sztul E
Neurobiol Dis; 2011 Jan; 41(1):11-22. PubMed ID: 20732421
[TBL] [Abstract][Full Text] [Related]
17. Research progress on the role of extracellular vesicles in neurodegenerative diseases.
Li Z; Wang X; Wang X; Yi X; Wong YK; Wu J; Xie F; Hu D; Wang Q; Wang J; Zhong T
Transl Neurodegener; 2023 Sep; 12(1):43. PubMed ID: 37697342
[TBL] [Abstract][Full Text] [Related]
18. Extracellular Vesicles Physiological Role and the Particular Case of Disease-Spreading Mechanisms in Polyglutamine Diseases.
Moreira R; Mendonça LS; Pereira de Almeida L
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830171
[TBL] [Abstract][Full Text] [Related]
19. Extracellular Vesicle as a Source of Alzheimer's Biomarkers: Opportunities and Challenges.
Lee S; Mankhong S; Kang JH
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30965555
[TBL] [Abstract][Full Text] [Related]
20. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
Nagai Y; Fujikake N; Popiel HA; Wada K
Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
